| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 16.60▼ | 18.52▼ | 19.05▼ | 20.20▼ | 19.43▼ |
| MA10 | 17.27▼ | 19.91▼ | 20.20▼ | 20.33▼ | 21.27▼ |
| MA20 | 17.96▼ | 20.61▼ | 20.85▼ | 20.01▼ | 24.26▼ |
| MA50 | 19.91▼ | 21.13▼ | 20.81▼ | 22.61▼ | 23.81▼ |
| MA100 | 20.63▼ | 20.86▼ | 20.47▼ | 24.65▼ | 22.18▼ |
| MA200 | 20.98▼ | 20.48▼ | 20.06▼ | 23.49▼ | 21.54▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.100▼ | -0.493▼ | -0.516▼ | 0.048▲ | -0.925▼ |
| RSI | 21.689▼ | 10.042▼ | 15.235▼ | 25.730▼ | 31.606▼ |
| STOCH | 19.493▼ | 15.238▼ | 30.887 | 58.553 | 12.350▼ |
| WILL %R | -79.690▼ | -89.739▼ | -89.739▼ | -90.480▼ | -95.730▼ |
| CCI | -110.025▼ | -185.532▼ | -235.952▼ | -271.897▼ | -93.860 |
| RSI | $ACAD RSI(14) Crossed Below 50 | Set Alert |
| ▼ RSI | $ACAD RSI(14) Crossed Below 30 | Set Alert |
| MA | $ACAD Price Crossed Below MA(26) | Set Alert |
| MA | $ACAD Price Crossed Below MA(13) | Set Alert |
| MA | $ACAD Price Crossed Below MA(7) | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 60 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 30 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 20 Days Low | Set Alert |
| ▼ BREAK | $ACAD Price Breaks 10 Days Low | Set Alert |
| CDL | $ACAD Engulfing Candlestick Pattern Detected | Set Alert |
|
Wednesday, November 04, 2026 11:15 PM
ACADIA Pharmaceuticals Inc (ACAD) posted $342 million in quarterly revenue and lifted its Debut outlook, even as the remlifanserin Phase 2 study narrowly missed statistical significance.
|
|
Wednesday, November 04, 2026 05:14 PM
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and ...
|
|
Thursday, September 24, 2026 08:26 PM
ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/11/26 | 21.41 | 21.655 | 15.855 | 16.50 | 12,024,424 |
| 06/11/26 | 21.00 | 21.45 | 20.59 | 21.23 | 1,770,800 |
| 05/11/26 | 21.98 | 22.63 | 21.14 | 21.24 | 6,022,172 |
| 04/11/26 | 21.18 | 21.54 | 20.51 | 21.47 | 4,545,764 |
| 03/11/26 | 20.50 | 20.815 | 20.45 | 20.57 | 1,704,708 |
| 02/11/26 | 20.71 | 20.7575 | 20.25 | 20.47 | 1,380,873 |
| 30/10/26 | 20.88 | 21.01 | 20.49 | 20.59 | 1,134,345 |
| 29/10/26 | 20.61 | 20.88 | 20.50 | 20.76 | 2,193,597 |
| 28/10/26 | 20.00 | 20.35 | 20.00 | 20.32 | 1,332,078 |
| 27/10/26 | 19.58 | 20.29 | 19.51 | 20.17 | 1,332,125 |
|
|
||||
|
|
||||
|
|